Compare NeoGenomics Inc. Common Stock (NEO) vs Onto Innovation (ONTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NeoGenomics Inc. Common Stock vs Onto Innovation — how do they compare? NeoGenomics Inc. Common Stock trades at $16.83 (market cap $2.14B), while Onto Innovation trades at $232 (market cap $12.93B). The key difference: Onto Innovation is far larger — about 6× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, Onto Innovation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and Onto Innovation for 7 Days on average.
| NEO | ONTO | |
|---|---|---|
Market Cap | $2.14B | $12.93B |
Volume | 2,228,400 | 1,098,259 |
Sector | Health | Technology |
52-Week High | $19.91 | $378.45 |
52-Week Low | $7.19 | $124.09 |
Typical Hold Time | 0 Days | 7 Days |
Enterprise Value | $2.44B | $12.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ONTO trades at $263.55, down 3.72% with bearish technical signals but strong analyst support. The stock shows mixed earnings performance with a Q2 2026 beat but misses in prior quarters. Revenue grew to $1.01B in 2025 with 11.84% net margin, though valuation remains elevated at P/E 98.71. Recent news highlights a $1.1B backlog and strategic partnerships in semiconductor manufacturing.
Outlook remains positive with 100% analyst buy ratings and $387 consensus target suggesting 47% upside. Key risks include high valuation multiples and semiconductor cycle volatility. Growth catalysts include AI-driven demand and Dragonfly G5 product momentum, though execution on backlog conversion is critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NeoGenomics Inc. Common Stock
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →About Onto Innovation
Onto Innovation provides process control solutions for semiconductor manufacturing. Its inspection and metrology systems help chipmakers measure, analyze, and detect defects on wafers and advanced packages.
Read more on ONTO →
